Adalimumab biosimilar - Pharma Research BIO/Genor Biopharma
Alternative Names: BCD-100; GB 232; Humira biosimilar - Pharma Research BIO/Genor BiopharmaLatest Information Update: 28 Oct 2022
Price :
$50 *
At a glance
- Originator Genor Biopharma
- Developer Genor Biopharma; Pharma Research BIO
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in China (SC)
- 21 Oct 2020 Preclinical development is still ongoing in China (Genor Biopharma pipeline, October 2020)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Autoimmune-disorders in South Korea (SC, Injection)